Aykaş, FatmaKarakuş, VolkanSevindik, Ömür Gökmen2023-03-092023-03-092022Aykaş, F., Karakuş, V. ve Sevindik, Ö. G. (2022). Successful use of split dose intravenous daratumumab in an overweight multiple myeloma patient after first dose life threatening infusion-related reaction. Clinical Lymphoma, Myeloma & Leukemia içinde (S48-S49. ss.).2152-26502152-2669https://hdl.handle.net/20.500.12511/10588Introduction: There is a paucity of data regarding the best practice to institute iv Daratumumab (D) in morbid obese patients regarding the infusion rate and duration, optimal dosing, and ideal way to cope with the infusion related reactions (IRR). We wanted to present the fi rst split dose D infusion experience in a morbid obese MM case whose D was interrupted because of a grade 3 IRR.eninfo:eu-repo/semantics/embargoedAccessIntravenous DaratumumabInfusion-Related ReactionMyeloma PatientConference Object22SupplementS48S49Q3000895909200081